The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

@article{Jakubowski2014TheIO,
  title={The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.},
  author={Joseph A. Jakubowski and Dominick Joseph Angiolillo and Chunmei Zhou and David S. Small and Brian A. Moser and Jurri{\"e}n M. ten Berg and Patricia B. Brown and Stefan James and Kenneth J. Winters and David Erlinge},
  journal={Thrombosis research},
  year={2014},
  volume={134 3},
  pages={
          552-7
        }
}
Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
TLDR
The primary outcome was ADP-induced platelet aggregation values within 24 h following loading dose of ticagrelor and prasugrel in patients with acute coronary syndromes (ACS).
Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia
TLDR
A popPK model was developed that provided reasonable parameter estimates, goodness-of-fit diagnostics, and visual predictive checks when applied to Pras-AM plasma concentrations in pediatric patients with SCA and did not correlate with measures of VOC or bleeding events in this population.
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
TLDR
Based on this substudy of a randomized trial, selecting prasugrel or clopidogrel based on PFT resulted in similar ischaemic outcomes as uniform prasUGrel therapy without HPR.
Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome
TLDR
A relatively low rate of high on-clopidogrel platelet reactivity is found even in an acute patient cohort, and a risk prediction model demonstrating moderate discriminative capacity is developed and internally validated.
Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events
TLDR
The predictive model of HTPR has useful discrimination and good calibration and may predict long-term MACE, and advanced age, higher body mass index, treatment with regular dual antiplatelet therapy, diabetes, and CYP2C19*2 or CYP19*3 carriers are significantly associated with HTPR.
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI
TLDR
Clopidogrel dose-adjusted plasma concentration in STEMI patients, as well as multivessel coronary artery disease, showed significance in predicting an unfavorable composite clinical outcome after 40-month follow-up.
Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate
TLDR
It is suggested that age, sex, smoking, or body weight may not substantially affect pharmacokinetic indices of PP1M, and the high interindividual variation of plasma concentrations implies that TDM may be helpful to enhancePP1M efficacy and tolerability.
Identifying clinically relevant sources of variability: The clopidogrel challenge
TLDR
High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its approval, and higher maintenance doses are required for CYP2C19 intermediate metabolizers and poor metabolizers compared to extensive metabolizers.
Sex and body weight are major determinants of venlafaxine pharmacokinetics
TLDR
The results highlight the role of different pharmacokinetically relevant parameters and foremost of sex as mediators for the effect of BMI on VEN metabolism.
...
1
2
...

References

SHOWING 1-10 OF 29 REFERENCES
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients
TLDR
HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel.
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
TLDR
VASP and LTA demonstrated concordance across the response range of P2Y(12) receptor blockade following thienopyridine LDs, and Pearson's correlation suggested a strong agreement between VASPand LTA (20 microM ADP) for MPA.
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
TLDR
The clopidogrel PK model included dose as a covariate indicating that a significantly less-than-proportional increase in Clop-AM exposure is expected over the dose range of 75–600 mg, thus, the model-predicted PD response is lower than might be anticipated given an 8-fold difference in dose and lower than that typically achieved following prasugrel 60 mg LD.
Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
TLDR
It is suggested that overweight patients may need a higher loading-dose of clopidogrel and/or an adjunct antithrombotic treatment to adequately inhibit platelet aggregation early after CS.
Clopidogrel resistance: role of body mass and concomitant medications.
Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
TLDR
Results demonstrate that in response to prasugrel, patients with SCD and healthy subjects have similar degrees of platelet inhibition and exposure to Pras-AM, and provide a basis for further study of pr asugrel in patients withSCD.
...
1
2
3
...